Launch Therapeutics (Launch Tx) is a clinical development company with a mission to disrupt the late-stage development paradigm, accelerate timelines to regulatory success, and bring new medicines to patients, faster. To deliver this, Launch Tx offers pharmaceutical and biotech partners a variety of innovative models that combine access to capital with deep drug development, medical, clinical operations, regulatory, and commercialization expertise. These models include significant risk financing, clinical co-development, and full in-licensing, all of which offer partners an aligned and efficient approach to realizing the potential of late-stage clinical programs across any therapeutic area. Founded in 2022, Launch Tx is backed by the respected and experienced professionals at Carlyle and its life sciences franchise, Abingworth. By combining the global network of Carlyle and Abingworth with the seasoned team of professionals at Launch Tx, both pharmaceutical and biotech companies have an ideal partner to advance their late-stage clinical programs.